Camp4 Therapeutics Announces CMP-002 Trial Clearance, $50M Financing Trigger

What Happened
Camp4 Therapeutics Corporation (CAMP) announced on July 27, 2026, that Australia’s Therapeutic Goods Administration and a local Human Research Ethics Committee cleared the company to initiate its Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder. The company filed the disclosure on Form 8-K (Regulation FD). As a result of this clearance, CAMP achieved the CTA Milestone and received a Price Threshold Waiver under the Securities Purchase Agreement dated September 9, 2025, which satisfied the Second Closing Trigger for a previously announced financing.

Key Details

• Regulatory clearance: TGA and local Human Research Ethics Committee clearance to start Phase 1/2 trial of CMP-002 (filed July 27, 2026).
• Financing trigger met: Achievement of the CTA Milestone and receipt of a Price Threshold Waiver satisfied the Second Closing Trigger under the September 9, 2025 Purchase Agreement.
• Potential proceeds: Subject to remaining conditions and investor participation, CAMP may receive up to approximately $50.1 million in gross proceeds in the Second Closing in exchange for up to 32,721,172 shares of common stock (or pre-funded warrants for certain investors).
• Timing: The Second Closing is expected to occur on or about August 3, 2026, subject to customary closing conditions.

Why It Matters
This filing signals both clinical and financing progress: regulatory clearance allows CAMP to start human testing of its lead candidate for a rare neurodevelopmental disorder, and meeting the financing trigger makes the company eligible for a sizeable funding tranche that could support the trial and other operations. For investors, the key takeaways are the advancement of the CMP-002 program and the potential infusion of up to $50.1M pending final closing conditions and investor participation.